NCT02451956View on ClinicalTrials.gov

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 7, 2015

Primary Completion Date

May 24, 2019

Study Completion Date

May 24, 2019

Conditions
Advanced Gastric Cancer
Interventions
DRUG

AZD5363

Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week

DRUG

paclitaxel

paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02451956 - Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy | Biotech Hunter | Biotech Hunter